Vitiligo, reactive oxygen species and T-cells

Clinical Science

Volumn 120, Issue 3, 2011, Pages 99-120

  Glassman, Steven J ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Immune system; Melanocyte; Reactive oxygen species (ROS); Skin; T cell; Vitiligo

Indexed keywords

ACETYLCHOLINE; ANTIOXIDANT; CATECHOL; CYTOKINE; HYDROGEN PEROXIDE; MELANIN; METHIONINE; MONOPHENOL MONOOXYGENASE; NITRITE; PROOPIOMELANOCORTIN; REACTIVE OXYGEN METABOLITE; TRYPTOPHAN;

AUTOIMMUNITY; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL LOSS; ENZYME ACTIVITY; GENETIC ANALYSIS; INJURY; MELANOCYTE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; VITILIGO;

ANTIOXIDANTS; AUTOIMMUNITY; HUMANS; HYDROGEN PEROXIDE; MELANINS; MELANOCYTES; REACTIVE OXYGEN SPECIES; T-LYMPHOCYTE SUBSETS; VITILIGO;

EID: 78751617257     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20090603     Document Type: Review

References (227)

1. Linthorst Homan, M. W., Spuls, P. I., de Korte, J., Bos, J. D., Sprangers, M. A. and van der Veen, M. A. (2009) The burden of vitiligo: patient characteristics associated with quality of life. J. Am. Acad. Dermatol. 61, 411-420
2. Millington, G. W. and Levell, N. J. (2007) Vitiligo: the historical curse of depigmentation. Int. J. Dermatol. 46, 990-995
3. Howitz, J., Brodthagen, H., Schwartz, M. and Thomsen, K. (1977) Prevalence of vitiligo. Epidemiological survey on the Isle of Bornholm, Denmark. Arch. Dermatol. 113, 47-52 (Pubitemid 8020128)
4. Boisseau-Garsaud, A. M., Garsaud, P., Cales-Quist, D., Helenon, R., Qeneherve, C. and Claire, R. C. (2000) Epidemiology of vitiligo in the French West Indies (Isle of Martinique). Int. J. Dermatol. 39, 18-20
5. Handa, S. and Kaur, I. (1999) Vitiligo: clinical findings in 1436 patients. J. Dermatol. 26, 653-657
6. Le Poole, C. and Boissy, R. E. (1997) Vitiligo. Semin. Cutan. Med. Surg. 16, 3-14
7. Hann, S. K. and Lee, H. J. (1996) Segmental vitiligo: clinical findings in 208 patients. J. Am. Acad. Dermatol. 35, 671-674
8. 2-mediated oxidation: a possible repair mechanism for DNA damage. FASEB J. 23, 3790-3807
9. Schallreuter, K. U., Wood, J. M., Pittelkow, M. R., Gutlich, M., Lemke, R., Rodl, W., Swanson, N. N., Hitzemann, K. and Ziegler, I. (1994) Regulation of melanin biosynthesis in the human epidermis by tetrahydrobiopterin. Science 263, 1444-1446
10. De Vijlder, H. C., Westerhof, W., Schreuder, G. M. Th., De Lange, P. and Claas, F. H. (2004) Difference in pathogenesis between vitiligo vulgaris and halo nevi associated with vitiligo is supported by an HLA association study. Pigment Cell Res. 17, 270-274
11. Taïeb, A and Picardo, M. (2007) The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res. 20, 27-35 (Pubitemid 46090162)
12. Falabella, R. (1988) Treatment of localized vitiligo by autologous minigrafting. Arch. Dermatol. 124, 1649-1655
13. Forschner, T., Buchholtz, S. and Stockfleth, E. (2007) Current state of vitiligo therapy-evidence-based analysis of the literature. J. Dtsch. Dermatol. Ges. 5, 467-475
14. Westerhof, W and Nieuweboer-Krobotova, L. (1997) Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. Arch. Dermatol. 133, 1525-1528
15. Kanwar, A. J., Dogra, S., Parsad, D. and Kumar, B. (2005) Narrow-band UVB for the treatment of vitiligo: an emerging effective and well-tolerated therapy. Int. J. Dermatol. 44, 57-60
16. Angrisani, R. M., Azevedo, M. F., Pereira, L. D., Lopes, C. and Garcia, M. V. (2009) A study on otoacoustic emissions and suppression effects in patients with vitiligo. Braz. J. Otorhinolaryngol. 75, 111-115
17. Sehgal, V. N. and Srivastava, G. (2007) Vitiligo: Compendium of clinico-epidemiological features. Indian J. Dermatol. Venereol. Leprol. 73, 149-156
18. Halder, R. M. and Chappell, J. L. (2009) Vitiligo update. Semin. Cutan. Med. Surg. 28, 86-92
19. Taïeb, A. and Picardo, M. (2009) Vitiligo. N. Engl. J. Med. 360, 10-169
20. Gawkrodger, D. J., Ormerod, A. D., Shaw, L., Mauri-Sole, I., Whitton, M. E., Watts, M. J., Anstey, A. V., Ingham, J. and Young, K. (2008) Guideline for the diagnosis and management of vitiligo. Br. J. Dermatol. 159, 1051-1076
21. Fitzpatrick, T. B., Miyomato, M and Ishikawa, K. (1967) The evolution of concepts of melanin biology. Arch. Dermatol. 96, 305-323
22. Ivanova, K., Block, I., Das, P. and Gerzer, R. (2006) Role of cyclic GMP signaling in the melanocyte response to hypergravity. Signal Transduct. 6, 406-413
23. Kollias, N., Sayre, R. M., Zeise, L. and Chedekel, M. R. (1991) Photoprotection by melanin. J. Photochem. Photobiol. B. 9, 135-160
24. Kobayashi, N., Nakagawa, A., Muramatsu, T., Yamashina, Y., Shirai, T., Hashimoto, M. W., Ishigaki, Y., Ohnishi, T. and Mori, T. (1998) Supranuclear melanin caps reduce ultraviolet induced DNA photoproducts in human epidermis. J. Invest. Dermatol. 110, 806-810
25. Le Poole, I. C., Mutis, T., van den Wijngaard, R. M., Westerhof, W., Ottenhoff, T., de Vries, R. R. and Das, P. K. (1993) A novel, antigen-presenting function of melanocytes and its possible relationship to hypopigmentary disorders. J. Immunol. 151, 7284-7292
26. Le Poole, I. C. and Luiten, R. M. (2008) Autoimmune etiology of generalized vitiligo. Curr. Dir. Autoimmun. 10, 227-243
27. Das, P. K., van den Wijngaard, R. M., Wankowicz-Kalinska, A. and Le Poole, I. C. (2001) A symbiotic concept of autoimmunity and tumor immunity: lessons from vitiligo. Trends Immunol. 22, 130-136
28. Gilhar, A., Paus, R. and Kalish, R. S. (2007) Lymphocytes, neuropeptides, and genes involved in alopecia areata. J. Clin. Invest. 117, 2019-2027
29. Anbar, T. S., Abdel-Raouf, H., Awad, S. S., Ragaie, M. H. and Abdel-Rahman, A. T. (2009) The hair follicle melanocytes in vitiligo in relation to disease duration. J. Eur. Acad. Dermatol. Venereol. 23, 934-939
30. Kitamura, R., Tsukamoto, K., Harada, K., Shimizu, A., Shimada, S., Kobayashi, T. and Imokawa, G. (2004) Mechanisms underlying the dysfunction of melanocytes in vitiligo epidermis: role of SCF/KIT protein interactions and the downstream effector, MITF-M. J. Pathol. 202, 463-475
31. Passerson, T. and Ortonne, J. -P. (2005) Physiopathology and genetics of vitiligo. J. Autoimmun. 25, 63-68
32. Dell'Anna, M. L. and Picardo, M. (2006) A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo. Pigment Cell Res. 19, 406-411
33. Westerhof, W. and d'Ischia, M. (2007) Vitiligo puzzle: the pieces fall in place. Pigment Cell Res. 20, 345-359
34. Schallreuter, K. U., Bahadoran, P., Picardo, M., Slominski, A., Elassiuty, E. H., Kemp, C., Giachino, C., Liu, J. B., Luiten, R. M., Lambe, T. et al. (2008) Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp. Dermatol. 17, 139-160
35. Boissy, R. E. and Spritz, R. A. (2009) Frontiers and controversies in the pathobiology of vitiligo: separating the wheat from the chaff. Exp. Dermatol. 18, 583-585
36. Le Poole, I. C., Das, P. K., van den Wijngaard, R. M., Bos, J. D. and Westerhof, W. (1993) Review of the etiopathomechanism of vitiligo: a convergence theory. Exp. Dermatol. 2, 145-153
37. Gauthier, Y., Cario-Andre, M., Lepreux, S., Pain, C. and Taïeb, A. (2003) Melanocyte detachment after skin friction in non lesional skin of patients with generalized vitiligo. Br. J. Dermatol. 148, 95-101
38. Namazi, M. R. (2007) Neurogenic dysregulation, oxidative stress, autoimmunity, and melanocytorrhagy in vitiligo: can they be interconnected? Pigment Cell Res. 20, 360-363
39. Moretti, S., Spallanzani, A., Amato, L., Hautmann, G., Gallerani, I., Fabiani, M. and Fabbri, P. (2002) New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res. 15, 87-92
40. Moretti, S., Fabbri, P., Baroni, G., Berti, S., Bani, D., Berti, E., Nassini, R., Lotti, T. and Massi, D. (2009) Keratinocyte dysfunction in vitiligo epidermis: cytokine microenvironment and correlation to keratinocyte apoptosis. Histol. Histopathol. 24, 849-857
41. Spritz, R. A. (2008) The genetics of generalized vitiligo. Curr. Opin. Autoimmun. 10, 244-257
42. Jin, Y., Riccardi, S. L., Gowan, K., Fain, P. R. and Spritz, R. A. (2009) Fine-mapping of vitiligo susceptibility loci on chromosomes 7 and 9 and interactions with NLRP1 (NALP1). J. Invest. Dermatol. 130, 774-783
43. Casp, C. B., She, J. -X. and McCormack, W. T. (2002) Genetic association of the Catalase gene (CAT) with vitiligo susceptibility. Pigment Cell Res. 15, 62-66
44. Onay, H., Pehlivan, M., Alper, S., Ozkinay, F. and Pehlivan, S. (2007) Might there be a link between mannose-binding lectin and vitiligo. Eur. J. Dermatol. 17, 146-148
45. Liu, L., Li, C., Gao, J., Li, K., Gao, L. and Gao, T. (2009) Genetic polymorphisms of glutathione S-transferase and risk of vitiligo in the Chinese population. J. Invest. Dermatol. 129, 2646-2652
46. Ren, Y., Yang, S., Xu, S., Gao, M., Huang, W., Gao, T., Fang, Q., Quan, C., Zhang, C., Sun, L. et al. (2009) Genetic variation of promoter sequence modulates XBP1 expression and genetic risk for vitiligo. PLoS Genet. 5, e1000523
47. Jin, Y., Birlea, S. A., Fain, P. R., Gowan, K., Riccardi, S. L., Holland, P. J., Mailloux, B. S., Sufit, A. J. D., Hutton, S. M., Amadi-Myers, A. et al. (2010) Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N. Eng. J. Med. 362, 1686-1697
48. Bishop, T. D., Demenais, F., Iles, M. M., Harland, M., Taylor, J. C., Corda, E., Randerson-Moor, J., Aitken, J. F., Avril, M. F., Azizi, E. et al. (2009) Genome-wide association study identifies three loci associated with melanoma risk. Nat. Genet. 41, 920-925
49. Huang, C. L., Nordlund, J. J. and Boissy, R. (2002) Vitiligo: a manifestation of apoptosis? Am. J. Clin. Dermatol. 3, 301-308
50. Ahsan, H., Ali, A. and Ali, R. (2003) Oxygen free radicals and systemic autoimmunity. Clin. Exp. Imunol. 131, 398-404
51. Beckman, J. S. and Koppenol, W. H. (1996) Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am. J. Physiol. 271, C1424-C1437
52. Halliwell, B. and Gutteridge, J. M. (1984) Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem. J. 219, 1-14
53. Marx, J. L. (1987) Oxygen free radicals linked to many diseases. Science 235, 529-531
54. Imlay, J. A. and Linn, S. (1988) DNA damage and oxygen radical toxicity. Science 240, 1302-1309
55. Linn, S. (1998) DNA damage by iron and hydrogen peroxide in vitro and in vivo. Drug Metab. Rev. 30, 313-326 (Pubitemid 28266865)
56. Namazi, M. R. (2009) Cytochrome-P450 enzymes and autoimmunity: expansion of the relationship and introduction of free radicals as the link. J. Autoimmun. Dis. 6, 4
57. Zhou, Z., Li, C. Y., Wang, T., Zhang, B. and Gao, T. W. (2009) Decreased methionine sulfoxide reductase A expression renders melanocytes more sensitive to oxidative stress: a possible cause for melanocyte loss in vitiligo. Br. J. Dermatol. 161, 504-509
58. Ogawa, F., Sander, C. S., Hansel, A., Oehrl, W., Kasperczyk, H., Elsner, P., Shimizu, K., Heinemann, S. H. and Thiele, J. J. (2006) The repair enzyme peptide methionine-S-sulfoxide reductase is expressed in human epidermis and upregulated by UVA radiation. J. Invest. Dermatol. 126, 947-949
59. Shigenaga, M. K., Hagen, T. M. and Ames, B. N. (1994) Oxidative damage and mitochondrial decay in aging. Proc. Natl. Acad. Sci. U. S. A. 91, 10771-10778
60. Briganti, S. and Picardo, M. (2003) Antioxidant activity, lipid peroxidation and skin diseases. What's new. J. Eur. Acad. Dermatol. Venereol. 17, 663-669
61. Bickers, D. R. and Athar, M. (2006) Oxidative stress in the pathogenesis of skin disease. J. Invest. Dermatol. 126, 2565-2575
62. 2-mediated oxidative stress affects human hair color by blunting methionine sulfoxide repair. FASEB J. 23, 2065-2075
63. 2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. J. Invest. Dermatol. Symp. Proc. 4, 91-96
64. Schallreuter, K. U., Wood, J. M. and Berger, J. (1991) Low catalase levels in the epidermis of patients with vitiligo. J. Invest. Dermatol. 97, 1081-1085
65. Moellmann, G., Klein-Angerer, S., Scollay, D. A., Nordlund, J. J. and Lerner, A. B. (1982) Extracellular granular material and degeneration of keratinocytes in the normally pigmented epidermis of patients with vitiligo. J. Invest. Dermatol. 79, 321-330
66. Bhawan, J. and Bhutani, L. K. (1983) Keratinocyte damage in vitiligo. J. Cutan. Pathol. 10, 207-212
67. Boissy, R. E., Liu, Y. Y., Medrano, E. E. and Nordlund, J. J. (1991) Structural aberration of the rough endoplasmic reticulum and melanosome compartmentalization in long-term cultures of melanocytes from vitiligo patients. J. Invest. Dermatol. 97, 395-404
68. Tobin, D. J., Swanson, N. N., Pittelkow, M. R., Peters, E. M. and Schallreuter, K. U. (2000) Melanocytes are not absent in lesional skin of long duration vitiligo. J. Pathol. 191, 407-416
69. Rokos, H., Wood, J. M., Hasse, S. and Schallreuter, K. U. (2008) Identification of epidermal L-tryptophan and its oxidation products by in vivo FT-Raman spectroscopy further supports oxidative stress in patients with vitiligo. J. Raman. Spectrosc. 39, 1214-1218
70. Shalbaf, M., Gibbons, N. C., Wood, J. M., Maitland, D. J., Rokos, H., Elwary, S. M., Marles, L. K. and Schallreuter, K. U. (2008) Presence of epidermal allantoin further supports oxidative stress in vitiligo. Exp. Dermatol. 17, 761-770
71. Koca, R., Armutcu, F., Altinyazar, H. C. and Gurel, A. (2004) Oxidant-antioxidant enzymes and lipid peroxidation in generalized vitiligo. Clin. Exp. Dermatol. 29, 406-409
72. Jain, D., Misra, R., Kumar, A. and Jaiswal, G. (2008) Levels of malondialdehyde and antioxidants in the blood of patients with vitiligo of age group 11-20 years. Indian J. Physiol. Pharmacol. 52, 297-301
73. Khan, R., Satyam, A., Gupta, S., Sharma, V. K. and Sharma, A. (2009) Circulatory levels of antioxidants and lipid peroxidation in Indian patients with generalized and localized vitiligo. Arch. Dermatol. Res. 301, 731-737
74. Darr, D. and Fridovich, I. (1994) Free radicals in cutaneous biology. J. Invest. Dermatol. 102, 671-675
75. Thannickal, V. J., Day, R. M., Klinz, S. G., Bastien, M. C., Larios, J. M. and Fanburg, B. L. (2000) Ras-dependent and -independent regulation of reactive oxygen species by mitogenic growth factors and TGF-β1. FASEB J. 14, 1741-1748
76. Schallreuter, K. U., Wood, J. M., Pittelkow, M. R., Buttner, G., Swanson, N., Korner, C. and Ehrke, C. (1996) Increased monoamine oxidase A activity in the epidermis of patients with vitiligo. Arch. Dermatol. Res. 288, 14-18
77. Schallreuter, K. U. (1999) A review of recent advances on the regulation of pigmentation in the human epidermis. Cell Mol. Biol. 45, 943-949
78. Schallreuter, K. U., Chiuchiarelli, G., Cemeli, E., Elwary, S. M., Gillbro, J. M., Spencer, J. D., Rokos, H., Panske, A., Chavan, B., Wood, J. M. and Anderson, D. (2006) Estrogens can contribute to hydrogen peroxide generation and quinone-mediated DNA damage in peripheral blood lymphocytes from patients with vitiligo. J. Invest. Dermatol. 126, 1036-1042
79. 4-dependent processes? J. Invest. Dermatol. 116, 167-174
80. 2 and pterin-6-carboxylic acid. Biochem. Biophys. Res. Commun. 292, 805-811
81. Shaker, O. G. and El-Tahlawi, S. M. (2008) Is there a relationship between homocysteine and vitiligo? A pilot study. Br. J. Dermatol. 159, 720-724
82. Picardo, M., Passi, S., Morrone, A., Grandinetti, M., Di Carlo, A. and Ippolito, F. (1994) Antioxidant status in the blood of patients with active vitiligo. Pigment Cell Res. 7, 110-115
83. Yildirim, M., Baysal, V., Inaloz, H. S. and Can, M. (2004) The role of oxidants and antioxidants in generalized vitiligo at tissue level. J. Eur. Acad. Dermatol. Venereol. 18, 683-686
84. Hazneci, E., Karabulut, A. B., Öztürk, C., Batcioglu, K., Dogan, G., Karaca, S. and Esrefoglu, M. (2005) A comparative study of superoxide dismutase, catalase, and glutathione peroxidase activities and nitrate levels in vitiligo patients. Int. J. Dermatol. 44, 636-640
85. Dammak, I., Boudaya, S., Ben Abdallah, F., Turki, H., Attia, H. and Hentati, B. (2009) Antioxidant enzymes and lipid peroxidation at the tissue level in patients with stable and active vitiligo. Int. J. Dermatol. 48, 476-480
86. Miyamoto, L. and Taylor, J. S. (2000) Chemical leukoderma. In Vitiligo: a Comprehensive Monograph on Basic and Clinical Science (Hann, S.-K. and Nordlund, J. J., eds), pp. 269-280, Blackwell Science Ltd. Oxford
87. Thorneby-Andresson, K., Sterner, O. and Hansson, C. (2000) Tyrosinase-mediated formation of a reactive quinone from the depigmenting agents, 4-tertbutylphenol and 4-tert-butylcatechol. Pigment Cell Res. 13, 33-38
88. Jimbow, K., Obata, H., Pathak, M. A. and Fitzpatrick, T. B. (1974) Mechanism of depigmentation by hydroquinone. J. Invest. Dermatol. 62, 436-449
89. Cummings, M. P. and Nordlund, J. J. (1995) Chemical leukoderma: fact or fancy. Am. J. Contact Dermatitis 6, 122-127
90. Taïeb, A. (2000) Intrinsic and extrinsic pathomechanisms in vitiligo. Pigment Cell Res. 13, 41-47
91. Boissy, R. E. and Manga, P. (2004) On the etiology of contact/occupational vitiligo. Pigment Cell Res. 17, 208-214
92. Manini, P., Napolitano, A., Westerhof, W., Riley, P. A. and d'Ischia, M. (2009) A reactive ortho-quinone generated by tyrosinase-catalyzed oxidation of the skin depigmenting agent monobenzone: self-coupling and thiol-conjugation reactions and possible implications for melanocyte toxicity. Chem. Res. Toxicol. 22, 1398-1405
93. Hariharan, V., Klarquist, J., Reust, M. J., Koshoffer, A., McKee, M. D., Boissy, R. E. and Le Poole, I. C. (2010) Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: relevance to skin depigmentation. J. Invest. Dermatol. 130, 211-220
94. Namazi, M. R. (2008) Proton pump inhibitors may trigger vitiligo by rendering melanocytes prone to apoptosis. Br. J. Dermatol. 158, 844-845
95. Schallreuter, K. U. and Rokos, H. (2007) From the bench to the bedside: proton pump inhibitors can worsen vitiligo. Br. J. Dermatol. 156, 1371-1373
96. Morrone, A., Picardo, M., de Luca, C., Terminali, O., Passi, S. and Ippolito, F. (1992) Catecholamines and vitiligo. Pigment Cell Res. 5, 65-69
97. Schallreuter, K. U., Wood, J. M., Pittelkow, M. R., Swanson, N. N. and Steinkraus, V. (1993) Increased in vitro expression of β2-adrenoceptors in differentiating lesional keratinocytes of vitiligo patients. Arch. Dermatol. Res. 285, 216-220
98. Schallreuter, K. U., Wood, J. M., Ziegler, I., Lemke, K. R., Pittelkow, M. R., Lindsey, N. J. and Gütlich, M. (1994) Defective tetrahydrobiopterin and catecholamine biosynthesis in the depigmentation disorder vitiligo. Biochim. Biophys. Acta 1226, 181-192
99. 2 increases de novo synthesis of (6R)-L-erythro-5, 6,7,8-tetrahydrobiopterin via GTP cyclohydrolase I and its feedback regulatory protein in vitiligo. J. Inherit. Metab. Dis. 32, 86-94
100. Papadopoulos, L., Bor, R., Legg, C. and Hawk, J. L. (1998) Impact of life events on the onset of vitiligo in adults: preliminary evidence for a psychological dimension in aetiology. Clin. Exp. Dermatol. 23, 243-248
101. Thöny, B., Auerbach, G. and Blau, N. (2000) Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem. J. 347, 1-16
102. 2 stress. J. Invest. Dermatol. 122, 307-313
103. Schallreuter, K. U., Zschiesche, M., Moore, J., Panske, A., Hibberts, N. A., Herrmann, F. H., Metelmann, H. R. and Sawatzki, J. (1998) In vivo evidence for compromised phenylalanine metabolism in vitiligo. Biochem. Biophys. Res. Commun. 243, 395-399
104. Le Poole, C., Van den Wijngaard, R., Smit, N. P. M., Oosting, J., Westerhof, W. and Pavel, S. (1994) Catechol-O-methyl transferase in vitiligo. Arch. Dermatol. Res. 286, 81-86
105. Namazi, M. R. (2005) Phenytoin as a novel anti-vitiligo weapon. J. Autoimmun. Dis. 2, 11-13
106. 2): potential and pitfalls. J. Invest. Dermatol. 126, 2576-2582
107. 2: more evidence for oxidative stress in vitiligo. Biochem. Biophys. Res. Commun. 315, 502-508
108. Schallreuter, K. U., Gibbons, N. C., Elwary, S. M., Parkin, S. M. and Wood, J. M. (2007) Calcium-activated butyrylcholinesterase in human skin protects acetylcholinesterase against suicide inhibition by neurotoxic organophosphates. Biochem. Biophys. Res. Commun. 355, 1069-1074
109. Graham, A., Westerhof, W. and Thody, A. J. (1999) The expression of alpha-MSH by melanocytes is reduced in vitiligo. Ann. N. Y. Acad. Sci. 885, 470-473
110. Spencer, J. D., Chavan, B., Marles, L. K., Kauser, S., Rokos, H. and Schallreuter, K. U. (2005) A novel mechanism in control of human pigmentation by β-melanocyte-stimulating hormone and 7-tetrahydrobiopterin. J. Endocrinol. 187, 293-302
111. Spencer, J. D., Gibbons, N. C., Rokos, H., Peters, E. M., Wood, J. M. and Schallreuter, K. U. (2007) Oxidative stress via hydrogen peroxide affects proopiomelanocortin peptides directly in the epidermis of patients with vitiligo. J. Invest. Dermatol. 127, 411-420
112. 2 oxidation of epidermal albumin in patients with vitiligo. J. Raman Spectrosc. 35, 125-130
113. Schallreuter, K. U., Gibbons, N. C., Zothner, C., Abou Elloof, M. M. and Wood, J. M. (2007) Hydrogen peroxide-mediated oxidative stress disrupts calcium binding on calmodulin: more evidence for oxidative stress in vitiligo. Biochem. Biophys. Res. Commun. 360, 70-75
114. 2-medaited oxidation in vitiligo. Endocrinology 149, 1638-1645
115. Hachiya, A., Kobayashi, A., Ohuchi, A., Takema, Y. and Imokawa, G. (2001) The paracrine role of stem cell factor/c-kit signaling in the activation of human melanocytes in ultraviolet B-induced pigmentation. J. Invest. Dermatol. 116, 578-586
116. Imokawa, G., Yada, Y. and Kimura, M. (1996) Signaling mechanisms of endothelin-induced mitogenesis and melanogenesis in human melanocytes. Biochem. J. 314, 305-312 (Pubitemid 2616899)
117. Jimenez-Cervantes, C., Martinez-Esparza, M., Perez, C., Daum, N., Solano, F. and Garcia-Borron, J. C. (2001) Inhibition of melanogenesis in response to oxidative stress: transient downregulation of melanocyte differentiation markers and possible involvement of microphthalmia transcription factor. J. Cell Sci. 114, 2335-2344
118. Gauthier, Y. (1996) The importance of Koebner's phenomenon in the induction of vitiligo lesions. Eur. J. Dermatol. 5, 704-708
119. Jezek, P and Hlavata, L. (2005) Mitochondria in homeostasis of reactive oxygen species in cell, tissues and organism. Int. J. Biochem. Cell Biol. 37, 2478-2503
120. Birlea, S. A., Costin, G. -E. and Norris, D. A. (2009) New insights on therapy with vitamin D analogs targeting the intracellular pathways that control repigmentation in human vitiligo. Medicinal Res. Rev. 29, 514-546
121. 2. Biochem. Biophys. Res. Commun. 325, 1412-1417
122. Jimbow, K., Chen, H., Park, J. -S. and Thomas, P. D. (2001) Increased sensitivity of melanocytes to oxidative stress and abnormal expression of tyrosinase-related protein in vitiligo. Br. J. Dermatol. 144, 55-65
123. Sravani, P. V., Babu, N. K., Gopal, K. V., Rao, A. R., Moorthy, B. and Rao, T. R. (2009) Determination of oxidative stress in vitiligo by measuring superoxide dismutase and catalase levels in vitiliginous and non-vitiliginous skin. Indian J. Dermatol. Venereol. Leprol. 75, 268-271
124. Wood, J. M., Gibbons, N. C., Chavan, B. and Schallreuter, K. U. (2008) Computer simulation of heterogeneous single nucleotide polymorphisms in the catalase gene indicates structural changes in the enzyme active site, NADPH-binding and tetramerization domains: a genetic predisposition for an altered catalase in patients with vitiligo? Exp. Dermatol. 17, 366-371
125. 2) in the epidermis of patients with vitiligo. J. Invest. Dermatol. 128, 808-815
126. Passi, S., Grandinetti, M., Maggio, F., Stancato, A. and De Luca, C. (1998) Epidermal oxidative stress in vitiligo. Pigment Cell Res. 11, 81-85
127. Beazley, W. D., Gaze, D., Panske, A., Panzig, E. and Schallreuter, K. U. (1999) Serum selenium levels and blood glutathione peroxidase activities in vitiligo. Br. J. Dermatol. 141, 301-303
128. Boisseau-Garsaud, A. -M., Garsaud, P., Lejoly-Boisseau, H., Robert, M., Quist, D. and Arveiler, B. (2002) Increase in total blood antioxidant status and selenium levels in black patients with active vitiligo. Int. J. Dermatol. 41, 640-642
129. Slominski, A., Paus, R. and Bomirski, A. (1989) Hypothesis: possible role for the melatonin receptor in vitiligo: discussion paper. J. R. Soc. Med. 82, 539-541
130. Reiter, R. J., Tan, D. X., Terron, M. P., Flores, L. J. and Czarnocki, Z. (2007) Melatonin and its metabolites: new findings regarding their production and their radical scavenging actions. Acta Biochim. Pol. 54, 1-9
131. Simon, H. U., Haj-Yehia, A. and Levi-Schaffer, F. (2000) Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 5, 415-418
132. Lee, Y. J., Chen, J. C., Amoscato, A. A., Bennouna, J., Spitz, D. R., Suntharalingham, M. and Rhee, J. G. (2001) Protective role of Bcl-2 in metabolic oxidative stress-induced cell death. J. Cell Sci. 114, 677-684
133. Van den Wijngaard, R. M., Aten, J., Scheepmaker, A., Le Poole, I. C., Tigges, A. J., Westerhof, W. and Das, P. K. (2000) Expression and modulation of apoptosis regulatory molecules in human melanocytes: significance in vitiligo. Br. J. Dermatol. 143, 573-581
134. Schallreuter, K. U., Kruger, C., Wurfel, B. A., Panske, A. and Wood, J. M. (2008) From basic research to the bedside: efficacy of topical treatment with pseudocatalase PC-KUS in 71 children with vitiligo. Int. J. Dermatol. 47, 743-753
135. Schallreuter, K. U., Moore, J., Behrens-Williams, S., Panske, A. and Harari, M. (2002) Rapid initiation of repigmentation in vitiligo with Dead Sea climatotherapy in combination with pseudocatalase (PC-KUS). Int. J. Dermatol. 41, 482-487
136. Bakis-Petsoglou, S., Le guay, J. L. and Wittal, R. (2009) A randomized double-blinded placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo. Br. J. Dermatol. 161, 721-722
137. Sanclemente, G., Garcia, J. J., Zuleta, J. J., Diehl, C., Correa, C. and Falabella, R. (2008) A double-blind, randomized trial of 005%betamethasone vs topical catalase/dismutase superoxide in vitiligo. J. Eur. Acad. Dermatol. Venereol. 22, 1359-1364
138. Elgoweini, M. and Nour El Din, N. (2009) Response of vitiligo to narrowband ultraviolet B and oral antioxidants. J. Clin. Pharmacol. 49, 852-855
139. Ongenae, K., Van Geel, N. and Naeyaert, J. -M. (2003) Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 16, 90-100
140. Schallreuter, K. U., Lemke, R., Brandt, O., Schwartz, R., Westhofen, M., Montz, R. and Berger, J. (1994) Vitiligo and other diseases: coexistence or true association. Dermatology 188, 269-275
141. Alkhateeb, A., Fain, P. R., Thody, A., Bennett, D. C. and Spritz, R. A. (2003) Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their relatives. Pigment Cell Res. 16, 208-214
142. Jandus, C., Bioley, G., Rivals, J. -P., Dudler, J., Speiser, D. and Romero, P. (2008) Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondyloarthritides. Arthritis Rheum. 58, 2307-2317
143. Foley, L. M., Lowe, N. J., Miseloff, E. and Tiwari, J. L. (1983) Association of HLA-DR4 with vitiligo. J. Am. Acad. Dermatol. 38, 39-40
144. Casp, C. B., She, J. X. and McCormack, W. T. (2003) Genes of the LMP/TAP cluster are associated with the human autoimmune disease vitiligo. Genes Immun. 4, 492-499
145. Venneker, G. T., Westerhof, W., de Vries, I. J., Drayer, N. M., Wolthers, B. G., de Waal, L. P., Bos, J. D. and Asghar, S. S. (1992) Molecular heterogeneity of the fourth component of complement (C4) and its genes in vitiligo. J. Invest. Dermatol. 99, 853-858
146. Blomhoff, A., Kemp, E. H., Gawkrodger, D. J., Weetman, A. P., Husebye, E. S., Akselsen, H. E., Lie, B. A. and Undlien, D. E. (2005) CTLA-4 polymorphisms are associated with vitiligo in patients with concomitant autoimmune diseases. Pigment Cell Res. 18, 55-58
147. Collins, S. M., Dominguez, M., Ilmarinen, T., Costigan, C. and Irvine, A. D. (2006) Dermatological manifestations of autoimmune polyendocrinopathy- candidiasis-ectodermal dystrophy syndrome. Br. J. Dermatol. 154, 1088-1093
148. Cantón, I., Akhtar, S., Gavalas, N. G., Gawkrodger, D. J., Blomhoff, A., Watson, P. F., Weetman, A. P. and Kemp, E. H. (2005) A single nucleotide polymorphism in the gene encoding lymphoid protein tyrosine phosphatase (PTPN22) confers susceptibility to generalized vitiligo. Genes Immun. 6, 584-587
149. Spritz, R. A., Gowan, K., Bennett, D. C. and Fain, P. R. (2004) Novel susceptibility loci on chromosomes 7 (AIS2) and 8 (AIS3), confirmation of SLEV1 on chromosome 17, and their roles in an autoimmune diathesis. Am. J. Hum. Genet. 74, 188-191
150. Austin, L. M. and Boissy, R. E. (1995) Mammalian tyrosinase-related protein-1 is recognized by autoantibodies from vitiliginous Smyth chickens. Am. J. Pathol. 146, 1529-1541
151. Farrokhi, S., Hojjat-Farsangi, M., Noohpisheh, M. K., Tahmasbi, R. and Rezaei, N. (2005) Assessment of the immune system in 55 Iranian patients with vitiligo. J. Eur. Acad. Dermatol. Venereol. 19, 706-711
152. Harning, R., Cui, J. and Bystryn, J. -C. (1991) Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J. Invest. Dermatol. 97, 1078-1080
153. Oyarbide-Valencia, K., van den Boorn, J. G., Denman, C. J., Li, M., Carlson, J. M., Hernandez, C., Nishimura, M. I., Das, P. K., Luiten, R. M. and Le Poole, I. C. (2006) Therapeutic implications of autoimmune vitiligo cells. Autoimmun Rev. 5, 486-492
154. + T-cell ratio. Wien. Med. Wochenschr. 159, 337-341
155. Mellouli, F., Ksouri, H., Dhouib, N., Torjmen, L., Abdelkefi, A., Ladeb, S., Ben Othman, T., Hmida, S., Ben Hassen, A. and Béjaoui, M. (2009) Possible transfer of vitiligo by allogeneic bone marrow transplantation: a case report. Pediatr. Transplant. 13, 1058-1061
156. Ortonne, J. P. and Alario, A. (1978) T and B lymphocytes in vitiligo. Arch. Dermatol. 261, 147-151
157. Grimes, P. E., Ghoneum, M., Stockton, T., Payne, C., Kelly, A. P. and Alfred, L. (1986) T cell profiles in vitiligo. J. Am. Acad. Dermatol. 14, 196-201
158. Soubiran, P., Benzaken, S., Bellet, C., Lacour, J. P. and Ortonne, J. P. (1985) Vitiligo: peripheral T-cell subset imbalance as defined by monoclonal antibodies. Br J. Dermatol. 113, 124-127
159. Halder, R. M., Walters, C. S., Johnson, B. A., Chakrabarti, S. G. and Kenney, Jr, J. A. (1986) Aberrations in T lymphocytes and natural killer cells in vitiligo: a flow cytometric study. J. Am. Acad. Dermatol. 14, 733-737
160. Hann, S. K., Park, Y. K., Chung, K. Y., Kim, H. I., Im, S. and Won, J. H. (1993) Peripheral blood lymphocyte imbalance in Koreans with active vitiligo. Int. J. Dermatol. 32, 286-289
161. + T-cell subset and evidence for peripheral T-cell activation. Int. J. Dermatol. 31, 321-326
162. + T-helper cells in non-segmental vitiligo. J. Dermatol. 29, 68-73
163. Basak, P. Y., Adiloglu, A. K., Koc, I. G., Tas, T. and Akkaya, V. B. (2008) Evaluation of activatory and inhibitory natural killer cell receptors in non-segmental vitiligo: a flow cytometric study. J. Eur. Acad. Dermatol. Venereol. 22, 970-976
164. Yu, H. S., Chang, K. L., Yu, C. L., Wu, M. T., Wu, C. S. and Wu, C. S. (1997) Alterations in IL-6, IL-8, GM-CSF, TNF-α and IFN-γ release by peripheral mononuclear cells in patients with active vitiligo. J. Invest. Dermatol. 108, 527-529
165. Tu, C. X., Fu, H. W. and Lin, X. R. (1999) Levels of soluble interleukin-2 receptor in the sera and skin tissue fluids of patients with vitiligo. J. Dermatol. Sci. 21, 59-62
166. Moretti, S., Spallanzani, A., Amato, L., Hautmann, G., Gallerani, I., Fabiani, M. and Fabbri, P. (2002) New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res. 15, 87-92 (Pubitemid 34536320)
167. Tu, C. X., Gu, J. S. and Lin, X. R. (2003) Increased interleukin-6 and granulocyte macrophage colony stimulating factor levels in the sera of patients with non-segmental vitiligo. J. Dermatol. Sci. 31, 73-78
168. Franczuk, A., Szepietowski, J. C. and Noworolska, A. (2004) Serum concentrations of interleukin-2 soluble receptor (IL-2 sR) in patients with vitiligo: relationship with type and extent of the disease. Acta Dermatovenereol. Croat. 12, 71-76
169. Grimes, P. E., Morris, R., Avaniss-Aghajani, E., Soriano, T., Meraz, M. and Metzger, A. (2004) Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J. Am. Acad. Dermatol. 51, 52-61
170. Zailaie, M. Z. (2005) Decreased proinflammatory cytokine production by peripheral blood mononuclear cells from vitiligo patients following aspirin treatment. Saudi Med. J. 26, 799-805
171. Birol, A., Kisa, U., Kurtipek, G. S., Kara, F., Kocak, M., Erkek, E. and Caglayan, O. (2006) Increased tumor necrosis factor α (TNF-α) and interleukin 1α (IL1-α) levels in the lesional skin of patients with nonsegmental vitiligo. Int. J. Dermatol. 45, 992-993
172. Mashiah, J and Brenner, S. (2007) Possible mechanisms in the induction of vitiligo-like hypopigmentation by topical imiquimod. Clin. Exp. Dermatol. 33, 74-76
173. Taher, Z. A., Lauzon, G., Maguiness, S. and Dytoc, M. T. (2009) Analysis of interleukin-10 levels in lesions of vitiligo following treatment with topical tacrolimus. Br. J. Dermatol. 161, 654-659
174. Basak, P. Y., Adiloglou, A. K., Ceyhan, A. M., Tas, T. and Akkaya, V. B. (2009) The role of helper and regulatory T cells in the pathogenesis of vitiligo. J. Am. Acad. Dermatol. 60, 256-260
175. Gokhale, B. B. and Mehta, L. N. (1983) Histopathology of vitiliginous skin. Int. J. Dermatol. 22, 477-480
176. Hann, S. K., Park, Y. K., Lee, K. G., Choi, E. H. and Im, S. (1992) Epidermal changes in active vitiligo. J. Dermatol. 19, 217-222
177. Galadari, E., Mehregan, A. H. and Hashimoto, K. (1993) Ultrastructural study of vitiligo. Int. J. Dermatol. 32, 269-271
178. Abdel-Naser, M. B., Kruger-Krasagakes, S., Krasagakis, K., Gollnick, H., Abdel-Fattah, A. and Orfanos, C. E. (1994) Further evidence for involvement of both cell mediated and humoral immunity in generalized vitiligo. Pigment Cell Res. 7, 1-8
179. Shiohara, T., Noriko Moria, B. S. and Nagashima, M. (1988) The lichenoid tissue reaction. Int. J. Dermatol. 27, 365-374
180. Gross, A., Tapia, F. J., Mosca, W., Perez, R. M., Briceno, L., Henriquez, J. J. and Convit, J. (1987) Mononuclear cell subpopulations and infiltrating lymphocytes in erythema dyschromicum perstans and vitiligo. Histol. Histopathol. 2, 277-283
181. Al Badri, A. M., Foulis, A. K., Todd, P. M., Gariouch, J. J., Stewart, D. G., Gracie, J. A. and Goudie, R. B. (1993) Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo. J. Pathol. 169, 203-206
182. Badri, A. M., Todd, P. M., Garioch, J. J., Gudgeon, J. E., Stewart, D. G. and Goudie, R. B. (1993) An immunohistological study of cutaneous lymphocytes in vitiligo. J. Pathol. 170, 149-155
183. + T cells at the perilesional site. Lab. Invest. 80, 1299-1309
184. + CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligandin-dependent mechanisms for tumor killing. J. Immunol. 161, 1220-1230
185. Moretti, S., Fabbri, P., Baroni, G., Berti, S., Bani, D., Berti, E., Nassini, R., Lotti, T. and Massi, D. (2009) Keratinocyte dysfunction in vitiligo epidermis: cytokine microenvironment and correlation to keratinocyte apoptosis. Histol. Histopathol. 24, 849-857
186. Arnold, R., Seifert, M., Asadulla, K. and Volk, H. D. (1999) Crosstalk between keratinocytes and T lymphocytes via Fas/Fas ligand interaction: modulation by cytokines. J. Immunol. 162, 7140-7147
187. Michaelsson, G. (1968) Vitiligo with raised borders. Acta Derm. Venereol. 48, 158-161
188. Attili, V. R. and Attili, S. K. (2008) Lichenoid inflammation in vitiligo - a clinical and histopathologic review of 210 cases. Int. J. Dermatol. 47, 663-669
189. Le Poole, I. C., van den Wijngaard, R. M., Westerhof, W. and Das, P. K. (1996) Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am. J. Pathol. 148, 1219-1228
190. Yagi, H., Tokura, Y., Furukawa, F. and Takigawa, M. (1997) Vitiligo with raised inflammatory borders: involvement of T cell immunity and keratinocytes expressing MHC class II and ICAM-1 molecules. Eur. J. Dermatol. 7, 19-22
191. + T cells to Type-1-like is associated with melanocyte loss in human vitiligo. Lab. Invest. 83, 683-695
192. Shresta, S., Smyth, Jr, J. R. and Erf, G. F. (1997) Profiles of pulp infiltrating lymphocytes at various times throughout feather regeneration in Smyth line chickens with vitiligo. Autoimmunity 25, 193-201
193. Del Prete, G. F., Vercelli, D., Tiri, A., Maggi, E., Mariotti, S., Pinchera, A., Ricci, M. and Romagnani, S. (1986) In vivo activated cytotoxic T cells in the thyroid infiltrate of patients with Hashimoto's thyroiditis. Clin. Exp. Immunol. 65, 140-147
194. Itoh, N., Hanafusa, T., Miyazaki, A., Miyagawa, J., Yamagata, K., Yamamoto, K., Waguri, M., Imagawa, A., Tamura, S., Inada, M. et al. (1993) Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J. Clin. Invest. 92, 2313-2322
195. Le Poole, I. C., Mutis, T., van den Wijngaard, R. M., Westerhof, W., Ottenhoff, T., de Vries, R. R. and Das, P. K. (1993) A novel, antigen-presenting function of melanocytes and its possible relationship to hypopigmentary disorders. J. Immunol. 151, 7284-7292
196. Comabella, M., Balashov, K., Issazadeh, S., Smith, D., Weiner, H. L. and Khoury, S. J. (1998) Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J. Clin. Invest. 102, 671-678
197. Nordlund, J. J., Kirkwood, J. M., Forget, B. M., Milton, G., Albert, D. M. and Lerner, A. B. (1983) Vitiligo in patients with metastatic melanoma: a good prognostic sign. J. Am. Acad. Dermatol. 9, 689-696
198. Bystryn, J. C., Rigel, D., Friedman, R. J. and Kopf, A. (1987) Prognostic significance of hypopigmentation in malignant melanoma. Arch. Dermatol. 123, 1053-1055
199. Cui, J. and Bystryn, J. C. (1995) Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells. Arch. Dermatol. 131, 314-318
200. Cavallari, V., Cannavo, S. P., Ussia, A. F., Moretti, G. and Albanese, A. (1996) Vitiligo associated with metastatic malignant melanoma. Int. J. Dermatol. 35, 738-740
201. Rosenberg, S. A. and White, D. E. (1996) Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis Tumor Immunol. 19, 81-84
202. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G. and Schadendorf, D. (1998) Vaccination of melanoma patients with peptide- or tumor-lysate pulsed dendritic cells. Nat. Med. 4, 328-332
203. Yee, C., Thompson, J. A., Roche, P., Byrd, D. R., Lee, P. P., Piepkan, M., Kenyon, K., Davis, M. M., Riddell, S. R. and Greenberg, P. D. (2000) Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J. Exp. Med. 192, 1637-1644
204. Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M. et al. (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-854
205. Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J. et al. (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. U.S.A. 100, 8372-8377
206. Luiten, R. M., Kueter, E. W., Mooi, W., Gallee, M. P., Rankin, E. M., Gerritsen, W. R., Clift, S. M., Nooijen, W. J., Weder, P., van de Kasteele, W. F. et al. (2005) Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J. Clin. Oncol. 23, 8978-8991
207. Anichini, A., Maccalli, C., Mortarini, R., Salvi, S., Mazzocchi, A., Squarcina, P., Herlyn, M. and Parmiani, G. (1993) Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J. Exp. Med. 177, 989-998
208. Kawakami, Y., Dang, N., Wang, X., Tupesis, J., Robbins, P. F., Wang, R. F., Wunderlich, J. R., Yannelli, J. R. and Rosenberg, S. A. (2000) Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J. Immunother. 23, 17-27
209. Becker, J. C., Guldberg, P., Zeuthen, J., Brecker, E. B. and Straten, P. T. (1999) Accumulation of identical T cells in melanoma and vitiligo-like leukoderma. J. Invest. Dermatol. 113, 1033-1038
210. + T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med. 190, 705-715
211. Jäger, E., Maeurer, M., Höhn, H., Karbach, J., Jäger, D., Zidianakis, Z., Bakhshandeh-Bath, A., Orth, J., Neukirch, C., Necker, A. et al. (2000) Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. Int. J. Cancer 86, 538-547 (Pubitemid 30249736)
212. Altman, J. D., Moss, P. A., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J. and Davis, M. M. (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94-96
213. Ogg, G. S., Dunbar, P. R., Romero, P., Chen, J. and Cerundolo, V. (1998) High frequency of skinhoming melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J. Exp. Med. 188, 1203-1208
214. + T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. J. Invest. Dermatol. 116, 891-897
215. Mandelcorn-Monson, R. L, Shear, N. H., Yau, E., Sambhara, S., Barber, B. H., Spaner, D. and DeBenedette, M. A. (2003) Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. J. Invest. Dermatol. 121, 550-556
216. Palermo, B., Garbelli, S., Mantovani, S., Scoccia, E., Da Prada, G. A., Bernabei, P., Avanzini, M. A., Brazzelli, V., Borroni, G. and Giachino, C. (2005) Qualitative difference between the cytotoxic T lymphocyte responses to melanocyte antigens in melanoma and vitiligo. Eur. J. Immunol. 35, 3153-3162
217. Garbelli, S., Mantovani, S., Palermo, B. and Giachino, C. (2005) Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity? Pigment Cell Res. 18, 234-242
218. Van den Boorn, J. G., Konijnenberg, D., Dellemijn, T. A., Wietze van der Veen, J. P., Bos, J. D., Melief, C. J., Vyth-Dreese, F. A. and Luiten, R. M. (2009) Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J. Invest. Dermatol. 129, 2220-2232
219. Rezaei, N., Gavalas, N. G., Weetman, A. P. and Kemp, E. H. (2007) Autoimmunity as an aetiological factor in vitiligo. J. Eur. Acad. Dermatol. Venereol. 21, 865-876
220. Degaco, C., Duftner, C., Grubeck-Loebenstein, B. and Schirmer, M. (2006) Imbalance of regulatory T cells in human autoimmune diseases. Immunology 117, 289-300
221. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182, 18-32
222. Min, W. P., Zhou, D., Ichim, T. E., Strejan, G. H., Xia, X., Yang, J., Huang, X., Garcia, B., White, D., Dutarte, P. et al. (2003) Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J. Immunol. 170, 1304-1312
223. Kroll, T. M., Bommiasamy, H., Boissy, R. E., Hernandez, C., Nickoloff, B. J., Mestril, R. and Le Poole, I. C. (2005) 4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo. J. Invest. Dermatol. 124, 798-806
224. + T cell immunity against a tumor/self-antigen is augmented by CD4 T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174, 2591-2601
225. Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M. and Stockinger, B. (2006) TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24, 179-189
226. Aflazi, B., Lombardi, G., Lechler, R. I. and Lord, G. M. (2007) The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin. Exp. Immunol. 148, 32-46
227. + T-cell dependent. Blood 108, 3818-3823